Anastrozole: Difference between revisions

Jump to navigation Jump to search
No edit summary
(No difference)

Revision as of 16:54, 12 June 2009

Anastrozole
Clinical data
Routes of
administration
oral
ATC code
Legal status
Legal status
  • Rx only (U.S.)
Pharmacokinetic data
Bioavailability83-85%
Protein binding40%
Metabolism85% hepatic
Elimination half-life72 hours
Excretion11% renal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H19N5
Molar mass293.366 g/mol

WikiDoc Resources for Anastrozole

Articles

Most recent articles on Anastrozole

Most cited articles on Anastrozole

Review articles on Anastrozole

Articles on Anastrozole in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Anastrozole

Images of Anastrozole

Photos of Anastrozole

Podcasts & MP3s on Anastrozole

Videos on Anastrozole

Evidence Based Medicine

Cochrane Collaboration on Anastrozole

Bandolier on Anastrozole

TRIP on Anastrozole

Clinical Trials

Ongoing Trials on Anastrozole at Clinical Trials.gov

Trial results on Anastrozole

Clinical Trials on Anastrozole at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Anastrozole

NICE Guidance on Anastrozole

NHS PRODIGY Guidance

FDA on Anastrozole

CDC on Anastrozole

Books

Books on Anastrozole

News

Anastrozole in the news

Be alerted to news on Anastrozole

News trends on Anastrozole

Commentary

Blogs on Anastrozole

Definitions

Definitions of Anastrozole

Patient Resources / Community

Patient resources on Anastrozole

Discussion groups on Anastrozole

Patient Handouts on Anastrozole

Directions to Hospitals Treating Anastrozole

Risk calculators and risk factors for Anastrozole

Healthcare Provider Resources

Symptoms of Anastrozole

Causes & Risk Factors for Anastrozole

Diagnostic studies for Anastrozole

Treatment of Anastrozole

Continuing Medical Education (CME)

CME Programs on Anastrozole

International

Anastrozole en Espanol

Anastrozole en Francais

Business

Anastrozole in the Marketplace

Patents on Anastrozole

Experimental / Informatics

List of terms related to Anastrozole

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Anastrozole (INN, trade name: Arimidex®) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It has the effect of decreasing the amount of estrogens that the body makes.

Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial represents a long-term follow-up study of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both.[1] After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized breast cancer that is estrogen receptor positive.

Usage for men

While officially indicated for women, this drug has proven effective in the off-label use of reducing estrogens (in particular and more importantly, estradiol) in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. Some athletes and body builders will also use anastrozole as a part of their steroid cycle to reduce and prevent symptoms of excess estrogens; in particular, gynecomastia and water retention.

Study data currently suggests that dosages of 0.5mg to 1mg a day reduce serum estradiol by about 50% in men, which differs from the typical reduction in postmenopausal women. However the reduction may be different for men with grossly elevated estradiol (clinical data is currently lacking).

Usage for children

This drug is frequently used in the treatment of growth disorder affected children to stop or slow the onset of puberty. The treatment of the growth disorder is through hormones which may trigger the early onset of puberty (precocious puberty). At the onset of puberty the bone growth plates begin to close. This can occur in children as young as 5 years old so for children severely behind in growth, the opportunity for increased growth is diminished. Arimidex is shown to slow or stop this process.

References

  1. Howell A, Cuzick J, Baum M; et al. (2005). "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer". Lancet. 365 (9453): 60–2. doi:10.1016/S0140-6736(04)17666-6. PMID 15639680.


External links

Template:Sex hormones Template:SIB

it:Anastrozolo

Template:WikiDoc Sources